Contribute Try STAT+ Today

File this under “Been down so long, looks like up to me.”

Just 43 percent of patient groups thought the pharmaceutical industry had an “excellent” or “good” reputation last year. Despite the poor showing, however, this is still an improvement — albeit, a modest one — from the 38 percent of patient groups that offered the same assessment in 2016, according to PatientView, a research firm that canvassed more than 1,300 patient groups from 95 countries.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • It was my intention to say that our scribe tried rather hard to find a positive side to these bleak numbers. Now that I have converted the intention into words, adieu!

  • Well, 38% “excellent” or “good” may be a “poor showing” for drug companies, but it’s no doubt much higher than the rating for journalists.

    • Hi James,

      Thanks for stopping by.

      The report was not an effort undertaken by STAT, but a research firm, as noted in the post. And the survey collected what patient groups think about those few dozen companies.

      I can understand your frustration, but I believe you’re shooting the messenger.

      ed at Pharmalot

Comments are closed.